Similarly, in NEMO-deficient patients caused by defects in IKBKG, HSCT resolves the immunodeficiency but does not cure intestinal inflammation.17 The indication, concept and prognosis of allogeneic HSCT differs from the autologous HSCT trialled in classical IBD.18,19. This evidence concerns the gene IKBKG and immune system disorder.